EMA — authorised 23 February 2001
- Application: EMEA/H/C/000331
- Marketing authorisation holder: Sanofi Winthrop Industrie
- Local brand name: Fasturtec
- Indication: Treatment and prophylaxis of acute hyperuricaemia, in order to prevent acute renal failure, in adults, children and adolescents (aged 0 to 17 years) with haematological malignancy with a high tumour burden and at risk of a rapid tumour lysis or shrinkage at initiation of chemotherapy.
- Status: approved